← Back to all trials
Recruiting
NCT05705583
A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma
Sex: All
Ages: 18 Years – N/A
Enrollment: 100
Sponsor: Zhejiang Cancer Hospital
Location: China
Summary
Immune checkpoint inhibitors targeting PD-1 or PD-L1 have been developed and clinical trials showning better response in unselected patients with metastatic renal cell carcinoma (RCC).
At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 RCC responsiveness.
The objective of this study is to develop and evaluate the utility of circulating exosomes as companion diagnostic biomarker for predicting response to immunotherapy in patients with RCC.
Eligibility Criteria
Inclusion Criteria:Advanced Metastatic RCCScheduled to initiate an immunocheckpoint inhibitors or in combination with themAge >= 18 yearsAble to provide informed consentExclusion Criteria:Other, unrelated, concomitant active, invasive malignancy
Source: ClinicalTrials.gov (NCT05705583). StuddyBuddy aggregates publicly available trial information.
